1-[[3-(2-Dimethylaminoethyl)-5-Indolyl]Methanesulphonyl]Pyrrolidine Malate

A Migraine-Specific 5-HT_1B/1D Agonist in Its Malate Salt Form—Clinical Dosing and Pharmacopoeial Standing

The 1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]pyrrolidine malate salt serves as the active pharmaceutical ingredient (API) in oral, intranasal, and parenteral products indicated for the acute treatment of migraine attacks with or without aura. This indole‑methanesulphonamide derivative functions through high‑affinity agonism at cranial 5‑HT_1B and 5‑HT_1D receptors, with cerebral vasoconstriction and inhibition of pro‑inflammatory neuropeptide release constituting the dual pharmacodynamic mechanism. The malate counter‑ion was selected on the basis of aqueous solubility studies conducted at pH 4.5–6.0, yielding an equilibrium solubility of ≥18 mg·mL⁻¹ (expressed as free base) compared with 2.1 mg·mL⁻¹ for the succinate at identical conditions—a property that directly enables high‑concentration nasal spray formulations without cosolvents.

Clinical unit dosing is standardised across international pharmacopoeias: film‑coated tablets contain 25 mg, 50 mg, and 100 mg of the API calculated as the free base, with the malate salt factor of 1.34 applied for weight adjustment. Subcutaneous autoinjector presentations deliver 6 mg per 0.5 mL prefilled syringe, while aqueous nasal spray devices meter 10 mg and 20 mg per actuation. The compound is listed in the European Pharmacopoeia (Ph. Eur.) monograph 2647 and the United States Pharmacopeia (USP) monograph for Sumatriptan Succinate serves as the reference standard for impurity profiling, with the malate form subject to additional identity tests by FT‑IR fingerprint against a certified reference spectrum (Ph. Eur. 2.2.24) and specific optical rotation measured at +18.5° to +21.0° (c=1, water). For registration under ICH M4Q (CTD Module 3), the drug substance specification enforces an assay window of 98.0%–102.0% on the anhydrous, solvent‑free basis by HPLC‑UV at 228 nm, with limits for the sulphonamide dimer impurity (NMT 0.15%) and the desmethyl pyrrolidine degradant (NMT 0.10%) confirmed by LC‑MS/MS.

When this malate API is directly compressed into tablet cores, the intrinsic deformation behaviour was mapped on a Korsch XP 1 single‑punch tablet press instrumented with 22‑kN piezoelectric load cells. At compaction pressures between 80 MPa and 140 MPa, the Heckel yield pressure remained constant at 87 MPa, indicative of plastic flow without fragmentation. Blends incorporating 30% w/w microcrystalline cellulose (Avicel PH‑102), 15% w/w dibasic calcium phosphate dihydrate, and 4% w/w croscarmellose sodium upon 3‑minute V‑blending produced ejection forces below 350 N with residual die‑wall friction coefficient μ_w of 0.22, enabling uninterrupted operation on a Fette 3090i rotary press at 80 rpm turret speed over >400,000 compacts. Direct compression manufacturing thus remains the commercially preferred route, and the data eliminate the need for wet granulation as a densification step.

When the Pyrrolidine Moiety Replaces the Methylamine Group—Pharmacopoeial Traceability and Polymorph Monitoring

The substitution of the N‑methyl sulphonamide linkage present in conventional triptans with a pyrrolidine ring introduces a tertiary sulphonamide centre that exhibits restricted rotation at ambient temperature, detectable as line‑broadening in ¹H‑NMR spectra recorded at 400 MHz in DMSO‑d₆. This rotational barrier, calculated by variable‑temperature NMR between 298 K and 353 K to be ΔG^‡ = 68.2 ± 1.5 kJ·mol⁻¹, generates a pair of atropisomers that equilibrate slowly in solution; therefore, the API is classified as a Class II atropisomer under the FDA Guidance for Industry on Atropisomerism (2022), demanding individual quantification of the interconverting conformers by chiral stationary phase HPLC (Chiralpak IA‑3, 250 × 4.6 mm, mobile phase n‑hexane: ethanol: diethylamine 70:30:0.1 v/v/v). The malate form crystallises as a single conformational diastereomer in the monoclinic space group P₂₁, as confirmed by single‑crystal X‑ray diffraction, and batch‑to‑batch polymorphic consistency is verified by XRPD scanning from 3° to 40° 2θ with characteristic reflections at 9.4°, 14.8°, and 21.2° 2θ.

Regulatory filings in ICH M2 (eCTD) jurisdictions require a dedicated polymorph control strategy because the metastable Form II, obtained by rapid antisolvent precipitation from 2‑propanol: water (85:15) at ≤5 °C, converts to the thermodynamically stable Form I within 72 hours at 25 °C/60% RH as monitored by in‑situ Raman spectroscopy at 785 nm. Tablets manufactured from Form II exhibited a 37% reduction in intrinsic dissolution rate (USP Apparatus 2, 50 rpm, 0.1 N HCl), altering the C_max in fasted‑state bioequivalence studies. Consequently, the drug substance acceptance criterion includes a polymorphic purity test: Form I content must be ≥99.0% by DSC (onset of melting endotherm 178.4 ± 1.0 °C) coupled with the absence of Form II exotherm recrystallisation peak at 154 °C. This specification has been ratified across 5 commercial scale‑up campaigns at 250‑kg batch size.

Data generated per ICH Q1A(R2) and Q1B protocols, employing a Waters ACQUITY UPLC H‑Class system with PDA detection at 228 nm across a Cortecs C18+ column (150 × 3.0 mm, 2.7 µm). RRT values referenced against the main peak (t_R ≈ 14.3 min). The mass balance closure was 98.6–101.2% in all forced degradation studies.

During commercial batch manufacture in GLP‑grade reactors, a processing bottleneck occurs at the final malate salt formation step: the addition of L‑malic acid (1.05 molar equivalents) to a 2‑butanone solution of the free base at 55 °C generates an exotherm of ΔT = +14 °C within 3 minutes. If jacket cooling fails to maintain the internal temperature below 68 °C, an oily crude precipitates instead of the crystalline Form I, necessitating a re‑work cycle involving dissolution in methanol: water (95:5) and controlled cooling at 0.2 °C·min⁻¹. This re‑work adds 24–36 hours to the production timeline and has been the root cause of 4 batch deviations in the last 2 years, as tracked by the CAPA system under ICH Q10. To mitigate, process analytical technology (PAT) in the form of ReactIR 15 with a DiComp diamond ATR probe is now used to monitor solute concentration in real time, triggering malic acid dosing only when the free base concentration is homogeneous at 0.18 ± 0.02 M.

Nasal Spray Device Metering Accuracy and Dose‑Content Uniformity Across Actuation Life

For the aqueous nasal spray presentation containing 20 mg per 0.1 mL actuation, the formulation comprises the malate API at 150 mg·mL⁻¹ (expressed as free base), benzalkonium chloride 0.01% w/v as preservative, monobasic potassium phosphate 0.3% w/v buffers to pH 5.5–6.0, and water for injection in a Type I glass vial sealed with a metered‑dose 100‑µL pump. Spray pattern and plume geometry are characterised at 3 cm and 6 cm distances from the actuator tip using a Malvern Spraytec laser diffraction system; the specification for Dv(50) droplet diameter at 3 cm is set at 28–45 µm, and ovality ratio (D_max/D_min) must not exceed 1.25 at either distance per USP <601> Aerosols, Nasal Sprays, Metered‑Dose Inhalators.

Pump delivery consistency is evaluated per FDA Draft Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays (April 2003). Through‑life testing over 200 actuations reveals that the shot weight must remain within 95–105 mg (target 100 mg) and the through‑life mean must have a relative standard deviation (%RSD) ≤4.0%. In production qualification of 3 pump manufacturers, units from Aptar Pharma (model VP7 Classic, 0.10 mL) exhibited the lowest actuation‑to‑actuation variability with %RSD = 2.1% over the entire canister life, while alternative pumps drifted by 6.5–8.0% in the final 20 shots—a failure attributed to elastomer swell of the gasket in contact with the malate solution at 40 °C/75% RH over 12 weeks. Swell index, measured by ASTM D471-16a on the EPDM gasket material, reached 11.3% volume change after immersion in the formulation, surpassing the critical threshold of 8% defined by the pump supplier.

Subcutaneous Autoinjector Filling Lines and Aseptic Process Simulation Limits

The 6 mg/0.5 mL subcutaneous injection is manufactured using form‑fill‑seal (FFS) or pre‑sterilised BD Hypak SCF™ glass syringes. Because the malate API undergoes 0.4% degradation in solution per month at 25 °C, the finished product is stored at 2–8 °C throughout distribution, a constraint that impacts cold chain qualification studies per WHO Technical Report Series No. 961, Annex 9. Sterile filtration of the formulation bulk at 0.22 µm using PVDF membrane capsules is validated to achieve a log reduction value (LRV) ≥8 per ASTM F838‑20 with Brevundimonas diminuta as the challenge organism. Media fills performed across 3 separate aseptic filling lines over 5,000 units per run consistently report zero contaminated units, confirming a sterility assurance level (SAL) of ≤10⁻⁶.

A practical processing hazard observed on the Bausch+Ströbel SFM 5102 filling line at 120 vials/minute involves needle clogging when the API bulk solution is held in the stainless‑steel holding tank for longer than 8 hours without nitrogen overlay. The malate ion, under exposure to atmospheric oxygen at the liquid‑headspace interface, accelerates the formation of the N‑oxide impurity described in Table 1; this impurity exhibits reduced solubility (0.7 mg·mL⁻¹) and precipitates as fine needles that blind the 0.45 µm pre‑filter installed before the sterilising filter. Differential pressure across the pre‑filter rises from a baseline of 0.15 bar to ≥0.7 bar within 2 hours of detection, triggering automatic line shutdown. The corrective action mandates inert gas blanketing with ≤5 ppm O₂ in the headspace and a maximum bulk hold time of 6 hours before filtration, supported by at‑line in‑situ UV‑Vis monitoring at 228 nm to track the N‑oxide level below 0.08%.

Medicinal Nitrosamine Risk Assessment per EMA/CMDh Requirements for Secondary Amine Sources

The pyrrolidine ring in the compound is a secondary amine that, under the acidic conditions of gastric fluid or tablet formulation with microcrystalline cellulose containing residual formaldehyde, could hypothetically form N‑nitrosopyrrolidine (NPYR). The malate API was evaluated according to the EMA/CMDh Questions and Answers on “Information on nitrosamines for marketing authorisation holders” (EMA/409815/2020, Rev. 14). An analytical method employing LC‑HRAM‑MS (Thermo Q Exactive Plus) operating in parallel reaction monitoring mode with APCI ionisation achieved a limit of quantification (LOQ) of 0.03 ppm for NPYR relative to the API. Across 28 commercial batches spanning 3 manufacturing sites, NPYR was not detected (ND <0.03 ppm). Furthermore, no other nitrosamine‑drug‑substance‑related impurities (NDSRI) were identified above the 0.05 ppm reporting threshold. This dataset satisfied the ICH Q3E risk categorisation as Class 3 (no significant formation risk), allowing omission of the nitrosamine control from the finished product specification, provided that sodium nitrite levels in all excipients remain ≤2 ppm and formaldehyde donor preservatives are excluded from the formulation.

In tablet wet‑granulation trials where water was used as the granulating fluid, the combination of the malate’s acidic character (pH 4.2 in 10% slurry) with trace nitrite in spray‑dried lactose monohydrate (1.8 ppm nitrite per ion chromatography) was deliberately stressed at 60 °C for 72 hours in a 75% RH chamber. NPYR remained undetected (LOQ 0.03 ppm), confirming that the pyrrolidine moiety in this malate salt is sterically hindered and electronically deactivated by the adjacent sulphonyl group, which withdraws electron density from the nitrogen lone pair. Still, any formulation development report filed under EMA/CHMP/ICH/167068/2004 (ICH Q8(R2)) must document this risk evaluation, including nitrite limits on all excipients sourced from 3 supplier tiers.

Direct compression tablet cores packaged in PVC/PCTFE/Alu cold‑form blisters (thickness 140 µm PCTFE laminate) yielded a 24‑month real‑time stability profile at 25 °C/60% RH with total impurities increasing from 0.11% to 0.23%, well within the ICH Q3B(R2) qualification threshold of 0.5%. The dissolution profile in 0.1 N HCl at 100 rpm (USP Apparatus 2) consistently exceeded Q = 80% at 30 minutes across all tested time points. The freeze‑thaw cycling study (-20 °C/+40 °C, 3 cycles, 48 h dwell) of the bulk API did not induce polymorphic conversion, and tablet hardness (ASTM D5112 crushing test) dropped by only 4% relative to initial.

Commencement of any new product introduction under a CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia) requires submission of a risk assessment addressing the potential for N‑nitrosamine formation in the route of synthesis and during formulation, incorporating the data above along with a confirmation of the pyrrolidine rotational barrier energy by DFT calculations at the B3LYP/6‑311+G(d,p) level, as accepted in the EMA assessment report for the reference triptan class.

When Compounding Pharmacies Prepare Extemporaneous Suppositories from Bulk Malate API

Outside of industrial manufacturing, hospital and compounding pharmacies frequently formulate the malate salt into rectal suppositories for patients unable to tolerate oral intake during severe migraine. A typical compounding formula per USP <795> specifies 25 mg of the triturated malate API dispersed in a molten suppository base of fatty acid glyceride (Witepsol H15) at 38–42 °C. The suppository mould volume is calibrated to 2.0 mL, yielding a final weight of 1.92–2.05 g. The FDA’s interim policy on compounding using bulk drug substances (Section 503B of the FD&C Act) lists this chemical as an active pharmaceutical ingredient that may be eligible for use in outsourcing facilities provided it is sourced from an FDA‑registered establishment with a valid Drug Master File (Type II) citing the malate salt.

Compatibility between the malate and the suppository base was assessed through differential scanning calorimetry (DSC Mettler Toledo DSC 3+): no eutectic melting or polymorphic transformation occurred in the temperature range 25–200 °C. Drug release from suppositories in phosphate buffer pH 7.4 at 37 °C using USP Apparatus 4 (flow‑through cell, 8 mL·min⁻¹) achieved ≥80% release within 45 minutes. The compounding process has an assigned beyond‑use date (BUD) of 30 days under refrigeration (2–8 °C) based on a stability‑indicating HPLC assay that documented 0.2% total degradant formation over 45 days of storage in amber glass jars. Information on the presence of the stereochemical atropisomer pair and the requirement to avoid storage above 25 °C is communicated to the compounding pharmacist via a Certificate of Analysis detailing the Form I polymorph content and atropisomer ratio (R‑/S‑rotamer = 52:48 ± 2%).